Oxidative Stress and Inflammation in Rheumatoid Arthritis: Molecular Mechanism and Therapeutic Approaches

Quratulann Sattar[1], Muhammad Umar Ijaz[1,*], Amara Tahir[1], Huma Naz[2], Mehrab Khalil[1], Nida Asif[1], Zainab Bibi[1] and Muhammad Zaid Salar[1]

[1]Department of Zoology, Wildlife and Fisheries, University of Agriculture, Faisalabad 38040, Pakistan
[2]Department of Zoology, Cholistan University of Veterinary and Animal Sciences, Bahawalpur, Pakistan
*Corresponding author: umar.ijaz@uaf.edu.pk

Abstract

Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by persistent synovial inflammation, joint destruction, and systemic complications. Among the key features of RA pathogenesis are oxidative stress and inflammation, which interact in a complex manner to perpetuate tissue damage. Oxidative stress, resulting from an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, plays a central role in the initiation and progression of RA. Excess ROS contributes to synovial cell proliferation, cartilage degradation, and bone erosion, while also amplifying inflammatory signaling pathways. Inflammation in RA is mediated by immune cells, such as macrophages and T lymphocytes, which produce pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines activate molecular pathways like NF-κB and JAK-STAT, driving the production of ROS and sustaining a cycle of oxidative damage and inflammation. The interplay between these processes exacerbates joint destruction and systemic manifestations. This chapter explores the molecular mechanisms linking oxidative stress and inflammation in RA and highlights their contributions to disease progression. It also reviews therapeutic strategies targeting these pathways, including the use of disease-modifying antirheumatic drugs (DMARDs), antioxidants, and emerging therapies such as nanotechnology and gene editing. By examining the process of oxidative stress, inflammation, and therapeutic approaches, this chapter aims to provide a comprehensive understanding of RA pathogenesis and innovative strategies to improve disease management.

Keywords: Antioxidants, Joint destruction, Inflammation, Rheumatoid arthritis, Autoimmune disorder

Cite this Article as: Sattar Q, Ijaz MU, Tahir A, Naz H, Khalil M, Asif N, Bibi Z and Salar MZ, 2025. Oxidative stress and inflammation in rheumatoid arthritis: Molecular mechanism and therapeutic approaches. In: García-Rubio VG, Alvi MA, Saeed Z and Ahmad M (eds), Foundations of Holistic Healing: Complementary and Alternative Medicine. Unique Scientific Publishers, Faisalabad, Pakistan, pp: 194-201. https://doi.org/10.47278/book.HH/2025.390

A Publication of Unique Scientific Publishers

Chapter No: 25-027

Received: 07-Jan-2025
Revised: 12-March-2025
Accepted: 12-Apr-2025

Introduction

Rheumatoid arthritis (RA) represents a systemic autoimmune disease that produces long-term synovitis leading to destructive joint damage combined with structural abnormalities and impaired joint activity. Worldwide more than 1% of people suffer from RA yet the condition mostly affects women as they represent about three patients for every male RA case (Smolen et al., 2016). RA emerges between ages 30 to 50 but doctors observed that it may occur at any stage of life. The systemic effects of RA include cardiovascular problems together with interstitial lung disease and reduced health resistance which subsequently increase mortality and disease severity (Silman & Pearson 2018). Patients suffering from RA experience significant social and financial costs because the disease results in reduced work ability along with increased medical expenses and diminished life-success measures. Some people face ongoing challenges in reaching long-term disease control even though biological and targeted synthetic disease-modifying antirheumatic medications (DMARDs) treatment options have improved recently (Figure 1) (Smolen et al., 2016).

The two pathogenic processes of inflammatory damage and oxidative damage function as essential elements in RA development. An imbalance between ROS production and antioxidant defense capacity results in structural damage to amino acids lipids and DNA in RA. Various studies have found increased markers of oxidative stress represented by malondialdehyde or MDA and peptide carbonyls in patients with RA (Tiosano et al., 2021). The pathways generate ROS that form a destructive pattern which leads to continuous oxidative strength with lasting inflammation (Bashir et al., 2022; Salar et al., 2024). The current chapter discusses the role of oxidative stress in the disease pathogenesis of RA. Moreover, it also describes the mechanisms and therapeutic approaches that could be taken to mitigate RA.

2. Oxidative Stress in Rheumatism

The condition referred to as OS results from uneven production of ROS relative to the antioxidant defense systems of the body. The unbalanced condition develops high levels of ROS that cause severe damage to both cells and molecules. The pathogenic component of RA depends heavily on oxidative stress because it increases both inflammation levels and joint deterioration and worsens disease progression (Kitasato & Furuya 2021).

Among the highly reactive oxygen compounds are superoxide anion ($O_2^{\bullet -}$) combined with hydrogen peroxide (H_2O_2) and hydroxyl radical (•OH) (Krol & Kepinska 2020). ROS form naturally from cellular metabolic processes to benefit both cellular signaling and immune response but cause damage to proteins as well as lipids and DNA when produced in excessive amounts. RA persistence results from both inflammation and bone destruction which begins from this specific tissue damage (Baxtiyorovna, 2025).

The ROS contains highly reactive oxygen-bearing molecules which include the superoxide anion ($O_2^{\bullet -}$) and hydrogen peroxide (H_2O_2) along with hydroxyl radicals (•OH). When cellular activities produce ROS these metabolites serve essential roles in cellular signaling and immunity but substantial overproduction leads to destructive harm to DNA, proteins, and lipids. Permanent inflammation and bone loss observed when dealing with RA stems from this specific type of tissue damage (Baxtiyorovna, 2025).

ROS neutralization relies upon the neutralizing capabilities of antioxidants that also include enzymes through superoxide dismutase (SOD), catalase, and glutathione peroxidase as well as non-enzymatic substances such as vitamins C and E. The balance between oxidants and antioxidants becomes unstable in RA patients while the disease pathology progresses through increased oxidation (Smith & Garcia 2020).



Fig. 1: The knee joint has healthy cartilage along with appropriate synovial fluid activity in cases of intact cartilage structure which supports joint integrity and minimizes damage to knees. The cartilage destruction in RA happens because of inflammatory responses which create reduced synovial cavity space leading to RA development.

2.1. Molecular Mechanisms of Oxidative Stress in RA

In patients with RA, the leading producers of ROS exist within the mitochondria and NADPH oxidase (NOX) enzyme systems. Mitochondria serve as the primary organelles for energy generation via phosphorylation of oxygen. The electron transport chain (ETC) transmits electrons until a small portion escapes to produce superoxide anions through oxygen interaction (Zhang et al., 2020). Under hypoxic conditions together with pro-inflammatory mediators including tumor necrosis factor-α and interleukin-1β the generation of ROS in mitochondria increases which causes worsening oxidative damage and synovial inflammation (Kavanaugh & Gottlieb 2017).

The NOX enzymes create ROS through membrane-associated complexes. Macrophages and neutrophils increase their NOX activity upon inflammatory stimuli within their immune cells (Eichwald et al., 2023). RA contains two mechanisms of action for ROS produced by NOX which serve both to amplify immune system signaling and to harm tissue directly. The levels of ROS increase in RA synovium due to NOX enzyme upregulation and this process promotes synovial fibroblast activation together with angiogenesis while leading to cartilage degradation (Andrabi et al., 2023).

RA develops through oxidative stress which disrupts immune tolerance in patients with the condition. ROS molecules trigger changes to self-antigens through reactions such as carbonylation until entirely new antigens emerge which send signals to the immune system that these substances are foreign (Ermis et al., 2024). The immune system produces autoantibodies such as anti-citrullinated protein antibodies (ACPAs) together with rheumatoid factor (RF) through stimulation by neoantigens that result in the specific markers of RA. The complement activation process begins when autoantibodies link with neoantigens causing the immune systems to recruit while intensifying synovial inflammation (Malavolta & Santoro, 2018). Figure 2. Illustrates the cellular and molecular pathways in the development and progression of RA.

The onset and progression of RA are governed by various cellular and molecular pathological mechanisms that function in a cohesive and coordinated way. The interplay of various environmental and genetic variables elevates the risk of developing RA. Autoimmune factors, including autoantigens alongside autoantibodies, as well as inflammatory chemicals released by triggered immune cells—such as various cytokines and chemokines—are established molecular characteristics that affect the clinical manifestations of RA, which is marked by swollen and tender joints and associated comorbidities.

The treatment of ROS and the promotion of antioxidant defenses emerge as a promising therapy for RA since oxidative stress plays an important role in this condition (Scioli et al., 2020). RA patients may benefit from agents that stabilize the electron transport chain (ETC) or scavenge ROS because both approaches lead to reduced oxidative damage in RA. Apocynin and other NOX inhibitors have undergone research to analyze their ability to block NOX enzymatic function while decreasing ROS generation within inflammatory joints (Iova et al., 2023).

The JAK-STAT and NF-κB pathways serve as objectives for novel treatment methods that indirectly manage oxidative stress and inflammation during RA. Patients with RA will experience decreased oxidative stress when they implement strategies such as antioxidant-rich diets and exercise (Huang et al., 2023). Skin tissue inflammation and joint destruction together with autoimmune system dysfunction stem

from oxidative stress which significantly drives RA pathogenesis. Research on ROS production mechanisms and their tissue-damaging effects enabled scientists to create new preventive measures against oxidative damage (Guo et al., 2024).



Fig. 2: Several cellular and molecular mechanisms take part in RA development and advancement.

3. Inflammation in Rheumatoid Arthritis

3.1 The Inflammatory Cascade in RA

The inflammatory process of RA promotes intricate molecular signaling between cytokines and immune cells and various pathways. Three inflammatory cytokines serve as the main components during this process: tumor necrosis factor-alpha (TNF-α) interleukin-1 (IL-1) and interleukin-6 (IL-6). The synovial tissue inflammation persists through cytokine activities that enable immune cell ordering and activation alongside sustaining the inflammatory conditions (Eichwald et al., 2023). The inflammatory process starts with TNF-α because it prompts cytokine production along with chemokine synthesis and enhances endothelial cell adhesion molecule display to draw leukocytes into the joint space. The inflammatory process becomes more potent through IL-1 and IL-6 which stimulates both acute-phase protein production and activates synovial joints. Fibroblasts also break down bone tissue (Janaszak-Jasiecka et al., 2023). Figure 3 shows the mechanism of inflammation in RA induction.



Fig. 3: Inflammatory cytokines IL-6 and TNF-alpha activate cells which leads cells to migrate to inflammation sites.

Certain genetic variations together with cytokines lead to prolonged inflammation that causes RA and other similar conditions in different body parts. The RA condition disrupts standard ROS levels throughout the body leading to multiple problematic events such as

unsteady oxygen metabolism and oxidative damage with weakened antioxidant defenses and these factors increase the risk for serious medical conditions. Excessive amounts of oxygen ions disrupt ROS levels thereby causing synovitis that medical professionals consider as a severe manifestation of RA.

The synovium tissue from RA patients contains numerous and evolving immune cells of which three main types include T cells and B cells together with macrophages. T cells of the CD4+ type together with Th1 and Th17 subsets direct the immune system coordination throughout the response. The cytokines Th1 cells generate interferon-gamma (IFN-γ) leading to activated macrophages while sustaining inflammation yet Th17 cells release IL-17 that directly activates synovial fibroblasts and bone marrow cells and osteoclasts thus promoting joint destruction (Salvagno et al., 2024). Activated macrophages produce additional cytokines after IFN-γ and TNF-α stimulation that drive tissue damage processes while triggering synovial hyperplasia and inflammatory responses through their enzymatic activity. Autoantibody production depends on B cells because these cells create both rheumatoid factors (RF) and antibodies against citrullinated proteins (ACPAs). Joint damage along with increased synovial inflammation arises from the formation of immune complexes that contain autoantibodies (Zhu et al., 2023).

3.2 Molecular Signaling Pathways

RA demonstrates complex inflammation pathways that particularly depend on the radioactive factor-kappa B (NF-κB) along with Janus kinase signal the transducer, and activation of transcription (JAK-STAT) pathways. NF-κB works as the main controller of inflammatory responses to direct the transcription of genes responsible for immune activities and cytokines along with cell survival mechanisms (Ziegler et al., 2020). TNF-α and IL-1 and pattern recognition receptor signaling both activate the NF-κB pathway in RA as they induce pro-inflammatory conditions. The activated NF-κB relocates to cell nuclei where it activates transcription of genes responsible for producing pro-inflammatory mediators among which are cytokines, chemokines, and the MMPs (matrix metalloproteinases). The inflammatory cascade functions to keep inflammation active then it works to damage tissue structures while also causing new blood vessel formation within synovial tissues (Perez-Torres et al., 2020).

RA heavily depends on the JAK-STAT signaling pathway which facilitates the effects of cytokines, particularly IL-6 and interferons. When cytokines bind their particular receptors, this process activates Janus kinases (JAKs). This activates the phosphorylation of STAT proteins. The phosphorylated STAT proteins bind to form nuclear double strands that control gene transcription linked to immune reactions and inflammatory reactions together with cell growth (Ding et al., 2023). RA causes JAK-STAT pathway dysregulation that leads to powerful cytokine signals that drive synovial tissue growth and immune responses as well as joint damage. RA management benefits from JAK inhibitor treatments such as tofacitinib and baricitinib which demonstrate excellent therapeutic effects on disease pathology (Heneka, 2024).

3.3 Persistent Inflammation and Joint Destruction

RA progresses when inflammation sustains due to persistent activation of immune system cells coupled with chemokine systems which form worsening circular cycles. The pro-inflammatory cytokines, including IL-6 and cytokines, not only initiate the immune system's response but also stimulate the synthesis of other arbitrators, such as chemical messengers and ROS, which exacerbate inflammatory and tissue injury (Li et al., 2017). This chronic inflammatory condition results in synovial hyperplasia, referred to as pannus development, characterized by the thickening of the synovium and infiltration by immune cells, fibroblasts, and newly developed blood vessels (Jang et al., 2021).

The stimulation of osteoclasts, which causes bone resorption, creates a correlation between inflammation and joint damage (Luo et al., 2024). In RA, bone formation is facilitated by cytokines, especially RANKL (receptor activator of nuclear factor-κB ligand), which is produced by B cells, T cells, and synovial fibroblasts. RANKL engages with its receptor, on osteoclast precursors, promoting their development upon activation (Chen et al., 2023).

4. Interplay between Oxidative Stress and Inflammation in RA

The development of RA depends on how inflammation and oxidative stress affect each other. Synovial inflammation along with joint injuries and systemic complications get worse through the linked actions of oxidative stress and inflammation processes. A thorough understanding of RA progression requires the study of ROS interactions with inflammatory cytokines as well as their cumulative joint-destroying effects according to Lavy et al. (2021). Superoxide anions together with hydrogen peroxide and hydroxyl radicals appear as normal metabolic byproducts through cellular processes. The synovial tissue of RA patients generates most of their ROS from three sources - mitochondria NADPH oxidase (NOX) and activated immune cells as reported by Maghsoudi et al. (2023). ROS inflict direct harm to proteins and lipids in addition to DNA while operating as signaling agents that intensify inflammatory situations. The transcription factors NF-κB and AP-1 function as redox-sensitive elements due to ROS activation to regulate gene expression of inflammatory cytokines together with chemokines and enzymes that degrade matrix. The process of redox regulation maintains inflammatory reactions and drives tissue breakdown as a mechanism of RA development (He et al., 2020).

RA experiences its main inflammation through inflammatory cytokines. The immune cell B cells together with T cells and mast cells and macrophages together with synovial fibroblasts produce cytokines (Hu et al., 2022). Inflammatory mediators control the inflammatory process through their role in initiating supplementary cytokine production and attracting immune cells while causing synovial tissue growth. Different methods allow pro-inflammatory cytokines to greatly elevate ROS production levels. The inflammatory cascade promoted by TNF-α and IL-1 activates two simultaneous processes: it impairs electron transport within mitochondria leading to increased ROS production and it simultaneously raises NOX levels and its enzymatic activity in immune cells. Through cytokine-generated ROS, the body enters a destructive feedback mechanism that intensifies oxidative stress and inflammatory processes (Pashangzadeh et al., 2021).

The simultaneous actions of ROS and inflammatory cytokines cause RA to worsen by damaging joints. The cellular damage from ROS

causes persistent structural modifications to collagen and proteoglycans in the extracellular matrix which breaks down cartilage support while allowing increased enzyme exposure (Yu & Zhao 2022). Pro-inflammatory cytokines promote additional damage by making synovial fibroblasts create MMPs along with aggrecanases which degrade cartilage along with joint structures. RA may develop severe manifestations including bone erosions because oxidative stress collaborates with inflammation to accelerate the destruction of both cartilage and bones (Kim & Lee 2025).

The joint structures receive direct damage from ROS and cytokines while these elements also modify bone development and loss. ROS facilitates the development and activation of osteoclasts, the cells responsible for bone resorption, via modifying signaling pathways, including the receptor activator of the nuclear factor-κB ligand (RANKL) pathway. Pro-inflammatory cytokines, especially TNF-α and IL-6, augment osteoclastogenesis by elevating RANKL expression and inhibiting the function of osteoprotegerin (OPG), a natural RANKL inhibitor. The synergistic effect of ROS and cytokines on osteoclasts results in increased bone resorption, contributing to the distinctive joint abnormalities seen in RA (Artimovic et al., 2024).

The interaction between oxidative stress and inflammation extends beyond localized joint disease to encompass systemic consequences in RA patients. Increased levels of ROS and pro-inflammatory cytokines correlate with a heightened risk for heart disease, metabolic disorders, and osteoarthritis (Liao et al., 2023). Endothelial cell dysfunction together with atherosclerosis and disturbed lipid metabolism results from systemic oxidative stress and inflammation to become major cardiovascular illness drivers in people with RA. The inflammatory and oxidative environment damages bone homeostasis which causes widespread bone depletion and increases fracture susceptibility (D'Onofrio et al., 2023).

Understanding the reciprocal relationship between oxidative stress and inflammation in RA has important implications for therapeutic strategies. Simultaneously targeting oxidative stress and inflammation may have synergistic advantages in reducing disease progression. Antioxidants, including synthesized SOD mimetics, have demonstrated the potential in diminishing ROS levels and mitigating oxidative damage in experimental RA models (Hernandez-Diazcouder et al., 2024). Similarly, polyphenols like curcumin and resveratrol, which are dietary antioxidants, have demonstrated anti-inflammatory and joint-protective qualities. However, by dramatically reducing inflammation and improving clinical outcomes, biological therapies that target pro-inflammatory cytokines, such as TNF inhibitors and IL-6 receptor antagonists, have revolutionized the treatment of RA (Hernandez-Navarro et al., 2024).

Treatment innovations target the complete system of connections running between OS and inflammatory conditions. Researchers are currently investigating dual-targeting representatives that influence redox-sensitive pathways of signaling through their effect on NF-κB inhibiting agents and JAK-STAT pathological agents to potentially break the harmful cycle of oxidative stress and inflammation. Patients with RA can enhance their endogenous antioxidant defenses by stopping smoking alongside physical exercise and an antioxidant-rich diet while also decreasing systemic inflammation levels (Tian et al., 2015).

5. Contemporary Pharmacological Interventions Aimed at Inflammation

Anti-inflammatory pharmaceutical medications function as the essential treatment method for RA. The pharmaceutical medicine known as methotrexate stands as the most frequently used DMARD in the basic treatment of RA (Lundberg and Weitzberg 2022). At the biochemical level methotrexate blocks dihydrofolate reductase to reduce lymphocyte growth and decrease harmful cytokines TNF-alpha and IL-6. The combination of methotrexate receives support from multiple traditional DMARDs such as hydroxychloroquine, leflunomide, and sulfasalazine based on patient feedback and disease progression levels (Yoon et al., 2021).

Biological DMARDs have revolutionized the treatment of RA by specifically targeting important inflammatory pathways. TNF inhibitors, such as etanercept, infliximab, and adalimumab, have shown remarkable efficacy in reducing inflammation, preventing joint degradation, and improving the quality of life for RA patients (Stykel and Ryan 2022). Two classes of alternative biological treatments include tocilizumab as an IL-6 receptor antagonist and rituximab as a form of B-cell-depleting medication for patients who experience inadequate results from TNF inhibitor therapy. The targeted synthetic DMARDs incorporate Janus kinase (JAK) inhibitors tofacitinib and baricitinib which manage inflammation-linked intracellular signaling pathways inside the cells. The current medicines demonstrate effectiveness yet they come with built-in restrictions according to Ren et al. (2020). Many patients experience either short-term remission failure or develop adverse symptoms which include heightened infection vulnerability digestive system complications and liver damage. Furthermore, patients and healthcare systems face financial challenges because of the high cost of biologics and JAK inhibitors. New therapeutic approaches need development because standard drug treatments fail to meet the complete needs of RA patient care requirements (Sulhan et al., 2020).

5.1 Antioxidants and Regulators of Oxidative Stress

Advances in biomedical research have made it easier to develop innovative treatment approaches that target the connection between inflammation and oxidative stress in RA. Organic anti-oxidants, including flavonoids, supplements, and polyphenols, have received much focus for their anti-inflammatory and redox-modulating characteristics (Jayaraj, et al., 2019). Flavonoids, present in vegetables, fruits, and beverages, neutralize ROS, impede lipid peroxidation, and suppress pro-inflammatory cytokine synthesis. Quercetin and catechins exhibit preventive benefits in experimental models of RA by diminishing oxidative stress and inflammation in the joints (Ghalehbandi et al., 2023).

Vitamins, especially folic acid and the antioxidant vitamin E, are recognized antioxidants that alleviate the effects of oxidative stress by reducing radicals that cause damage and restoring other antioxidants. Vitamin D, while not a direct antioxidant, demonstrates immunomodulatory effects and is associated with decreased disease activity in RA patients. Moreover, omega-3 fatty acids found in fish oil have antioxidant and anti-inflammatory properties, rendering them beneficial dietary supplements for the therapy of RA (Yoshida et al., 2022).

Synthetic antioxidants such as N-acetylcysteine (NAC), edaravone, and tempol have supplementary therapeutic promise. NAC, a cysteine precursor, restores intrinsic antioxidant activity and decreases ROS production. Edaravone, a free radical scavenger, has demonstrated effectiveness in diminishing synovial oxidative stress and cartilage deterioration in preclinical investigations. Notwithstanding these encouraging results, clinical trials examining synthetic antioxidants in RA are scarce, highlighting the need for additional research to determine their safety and usefulness (Han et al., 2020).

5.2 Novel Pharmaceutical Therapies

Progress in biomedical research has facilitated novel therapy strategies aimed at addressing the relationship between oxidative stress and inflammation in RA. CRISPR-Cas9 along with other gene editing technologies demonstrates meaningful potential to precisely control genes linked with pro-inflammatory and oxidative stress (Mintz et al., 2021). Strategic alterations to genes encoding TNF-α or NOX enzymes would block the unhealthy process in which inflammation and oxidative damage feed into each other. The initial stage of gene editing technology reveals capabilities for developing personalized and sustainable treatment of RA. The therapeutic potential of siRNA and antisense oligonucleotides – two RNA-based agents – represents an investigational approach according to Chakraborty and Ain (2017). The compounds function by stopping gene expression of pro-inflammatory cytokines in combination with oxidative stress mediator genes related to RA pathophysiology. Research has validated RNA-based treatments to reduce synovial inflammation and oxidative damage during preclinical trials but their clinical usage requires the resolution of delivery along with stability problems (Somasundaram et al., 2019).

Nanoparticles have advanced RA medicine distribution through enhancements of therapeutic product effectiveness and biodistribution. Radioactive small and nanoparticulate agents protect antioxidant substances anti-inflammatory agents and RNA molecules while delivering them to targeted joints. Research indicates that curcumin and resveratrol nanoparticles demonstrate elevated effectiveness for reducing oxidative stress and inflammation within arthritis animal models. The technology of administering nanoparticles reduces both adverse systemic effects and improves the precision of treatment delivery (Gao et al., 2023).

5.3 Lifestyle and Nutritional Modifications

Traditional RA therapies receive added effectiveness through non-drug lifestyle and nutritional approaches. The Mediterranean diet serves as an example of an anti-inflammatory eating plan that emphasizes vegetables whole grains and fruits alongside nuts and fatty sea products by eliminating refined products together with fatty meats (Daiber et al., 2019). The dietary patterns contain polyphenols along with omega-3 fatty acids that help decrease both inflammatory responses and oxidative stress. Anti-inflammatory dietary plans when followed by individuals with RA drive down disease activity levels while lessening pain alongside joint rigidity (Sudarshan et al., 2024).

Exercise is a crucial element in the management of RA, providing both physical and biochemical advantages. Consistent moderate-intensity exercise enhances joint mobility, muscle strength, and general quality of life in people with RA. Furthermore, exercise improves antioxidant defenses by increasing the levels of endogenous antioxidant enzymes, such as SOD and the enzyme catalase thereby diminishing oxidative stress (Ding, et al., 2025). It also regulates inflammatory responses by diminishing pro-inflammatory cytokine levels and enhancing the synthesis of anti-inflammatory cytokines, such as interleukin-10 (IL-10). Customized exercise regimens, encompassing aerobic and resistance training, can be designed to accommodate unique patient requirements and physical constraints (Carlstrom, et al 2024).

6. Future Perspectives

6.1 Gaps in Current Understanding

Notwithstanding considerable progress in comprehending RA pathogenesis, numerous gaps persist. The exact relationship between oxidative stress and immunological dysregulation in RA remains inadequately clarified. Although oxidative stress is recognized for exacerbating inflammation, its role as either a catalyst or a result of immune activation is still contentious (Casas et al., 2020). The role of many cell types, including fibroblast-like synoviocytes (FLS), macrophages, and neutrophils, in oxidative stress-induced joint injury necessitates additional investigation. Moreover, although antioxidants have been suggested as possible therapeutic agents, their effectiveness in clinical environments has been variable, highlighting the necessity for a more profound understanding of their processes and bioavailability (Sundararajan 2025)

6.2 Emerging Research areas Molecular Targets and Innovative Therapies

Recent research has found new molecular targets that may provide revolutionary therapy options for RA. A possible approach involves targeting oxidative stress-related enzymes, including NOX, myeloperoxidase (MPO), and SOD, to regulate ROS generation. Scientists have recognized transcription factor NF-E2-related factor 2 (Nrf2) as a promising therapeutic target since it controls antioxidant defense systems (Xue et al., 2025). Preclinical studies have shown that Nrf2 activators function as small molecule compounds in reducing RA-related oxidative stress with accompanying inflammation in animal subjects (Tabish et al., 2024). A new approach employs specific mitochondrial antioxidants MitoQ and SkQ1 to reduce ROS production in synovial tissues thus protecting the tissues from oxidative damage (Afrose et al., 2025). Medical researchers optimize biological medicines that target inflammatory pathways to achieve better results as well as reduce side effects. Medical research focuses on developing IL-6 monoclonal antibodies and those targeting IL-17 and GM-CSF as viable TNF inhibitor alternatives. Investigators explore the use of MSC treatment in cell medicine as a potential solution to manage immune response while reducing oxidative stress in RA patients. The implementation of nanoparticle technology within nanomedicine has enabled researchers to build delivery methods that target antioxidant and anti-inflammatory drugs specifically for joint areas requiring treatment. (Zeng et al., 2025).

Conclusion

Oxidative stress and inflammation are pivotal in the etiology of RA, propelling disease development and joint deterioration. While existing medications mostly concentrate on mitigating inflammation, addressing oxidative stress offers a promising supplementary strategy for enhancing RA therapy. Despite deficiencies in our comprehension, nascent research on molecular targets including NOX enzymes, Nrf2 activation, and mitochondria-targeted antioxidants presents novel therapeutic opportunities. Progress in biologics, cell-based therapeutics, and nanomedicine broadens the therapy spectrum, improving precision and effectiveness. The translational promise of these discoveries resides in personalized medicine tactics, utilizing biomarker profiling and multi-omics methodologies to customize therapies for specific patients. Progressing, the incorporation of these breakthroughs into clinical practice via meticulously structured trials and interdisciplinary research initiatives will be essential for the development of more effective and sustainable RA medications.

References

Afrose, D., Alfonso-Sánchez, S., & McClements, L. (2025). Targeting oxidative stress inpreeclampsia. *Hypertension in Pregnancy, 44*(1), 45-56.

Andrabi, S.M., Sharma, N.S., Karan, A., Shahriar, S.S., Cordon, B., Ma, B. & Xie, J. (2023). Nitric oxide: physiological functions, delivery, and biomedical applications. *Advanced Science,* 10(30), 2303259.

Artimovic, P., Spakova, I., Macejkova, E., Pribulova, T., Rabajdova, M., Marekova, M., & Zavacka, M. (2024). The ability of microRNAs to regulate the immune response in ischemia/reperfusion inflammatory pathways. *Genes & Immunity, 25*, 277-296.

Bashir, S., Harris, G., & Denman, M. A. (2022). Oxidative stress in rheumatoid arthritis: Pathogenic mechanisms and therapeutic implications. *Clinical Rheumatology, 41*(2), 115-129.

Baxtiyorovna, M.N., 2025. The Role of Endothelial Dysfunction in the Development of Hemostatic Disturbances in Rheumatoid Arthritis and Improving Treatment Strategies. *Journal of Medical Genetics and Clinical Biology, 2*(4), pp.47-51.

Carlstrom, M., Weitzberg, E., & Lundberg, J. O. (2024). Nitric Oxide Signaling and Regulation in the Cardiovascular System: Recent Advances. *Pharmacological Reviews*, *76*, 38-62.

Casas, A. I., Nogales, C., Mucke, H. A. M., Petraina, A., Cuadrado, A., Rojo, A. I., Ghezzi, P., Jaquet, V., Augsburger, F., & Dufrasne, F. (2020). On the Clinical Pharmacology of Reactive Oxygen Species. *Pharmacological Reviews*, *72*, 801-828.

Chakraborty, S., & Ain, R. (2017). Nitric-oxide synthase trafficking inducer is a pleiotropic regulator of endothelial cell function and signaling. *Journal of Biological Chemistry*, *292*, 62-66.

Chen, S., Saeed, A., Liu, Q., Jiang, Q., Xu, H., Xiao, G.G., Rao, L., & Duo, Y. (2023). Macrophages in immunoregulation and therapeutics. *Signal Transduction and Targeted Therapy, 8,* 207-212.

D'Onofrio, N., Prattichizzo, F., Martino, E., Anastasio, C., Mele, L., La Grotta, R., Sardu, C., Ceriello, A., Marfella, R., & Paolisso, G. (2023). MiR-27b attenuates mitochondrial oxidative stress and inflammation in endothelial cells. *Redox Biology, 62,* 102681.

Daiber, A., Xia, N., Steven, S., Oelze, M., Hanf, A., Kroller-Schon, S., Munzel, T., & Li, H. (2019). New Therapeutic Implications of Endothelial Nitric Oxide Synthase (eNOS) Function/Dysfunction in Cardiovascular Disease. *International Journal of Molecular Sciences, 20*, 187-190.

Ding, C., Liu, Q., You, X., Yuan, J., Xia, J., Tan, Y., Hu, Y. & Wang, Q. (2025). Investigating the molecular mechanism of epimedium herb in treating rheumatoid arthritis through network pharmacology, molecular docking, and experimental validation. *Molecular Diversity, 1*, 19-21.

Ding, Q., Hu, W., Wang, R., Yang, Q., Zhu, M., Li, M., Cai, J., Rose, P., Mao, J., & Zhu, Y. Z. (2023). Signaling pathways in rheumatoid arthritis: Implications for targeted therapy. Signal *Transduction and Targeted Therapy, 8*, 6-8.

Eichwald, T., da Silva, L. B., Staats Pires, A. C., Niero, L., Schnorrenberger, E., Filho, C. C., Espindola, G., Huang, W. L., Guillemin, G. J., & Abdenur, J. E. (2023). Tetrahydrobiopterin: Beyond Its Traditional Role as a Cofactor. *Antioxidants, 12,* 10-37.

Ermis, E., Nargis, T., Webster, K., Tersey, S. A., Anderson, R. M., & Mirmira, R. G. (2024). Leukotriene B4 receptor 2 governs macrophage migration during tissue inflammation. *Journal of Biological Chemistry, 300*, 105561.

Gao, D., Asghar, S., Hu, R., Chen, S., Niu, R., Liu, J., Chen, Z., & Xiao, Y. (2023). Recent advances in diverse nanosystems for nitric oxide delivery in cancer therapy. *Acta Pharmaceutica Sinica, 13*, 14-21.

Ghalehbandi, S., Yuzugulen, J., Pranjol, M. Z. I., & Pourgholami, M. H. (2023). The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF. *European Journal of Pharmacology, 949*, 175586.

Guo, Q., Jin, Y., Chen, X., Ye, X., Shen, X., Lin, M., Zeng, C., Zhou, T., & Zhang, J. (2024). NF-kappaB in biology and targeted therapy: New insights and translational implications. *Signal Transduction and Targeted Therapy*, *9*(53), 18-23.

Han, Y., Liu, D., & Li, L. (2020). PD-1/PD-L1 pathway: Current researches in cancer. *American Journal of Cancer Research, 10*(67), 727-742.

Heneka, M. T., van der Flier, W. M., Jessen, F., Hoozemanns, J., Thal, D. R., Boche, D., Brosseron, F., Teunissen, C., Zetterberg, H., & Jacobs, A. H. (2024). Neuroinflammation in Alzheimer disease. *Nature Reviews Immunology, 8,* 10-15.

Hernandez-Diazcouder, A., Romero-Nava, R., Del-Rio-Navarro, B. E., Sanchez-Munoz, F., Guzman-Martin, C. A., Reyes-Noriega, N., Rodriguez-Cortes, O., Leija-Martinez, J. J., Velez-Resendiz, J. M., & Villafana, S. (2024). The Roles of MicroRNAs in Asthma and Emerging Insights into the Effects of Vitamin D3 Supplementation. *Nutrients*, *16*, 341-346.

Hernandez-Navarro, I., Botana, L., Diez-Mata, J., Tesoro, L., Jimenez-Guirado, B., Gonzalez-Cucharero, C., Alcharani, N., Zamorano, J. L., Saura, M., & Zaragoza, C. (2024). Replicative Endothelial Cell Senescence May Lead to Endothelial Dysfunction by Increasing the BH2/BH4 Ratio Induced by Oxidative Stress, Reducing BH4 Availability, and Decreasing the Expression of eNOS. *International Journal of Molecular Sciences, 25*, 90-98.

Hu, J., Huang, S., Liu, X., Zhang, Y., Wei, S., & Hu, X. (2022). miR-155: An Important Role in Inflammation Response. *Journal of Immunology Research, 6,* 7437281.

Huang, J. B., Chen, Z. R., Yang, S. L., & Hong, F. F. (2023). Nitric Oxide Synthases in inflammatory Diseases: Anti-Inflammatory and Pro-Inflammatory Effects. *Frontiers in Immunology, 13*, 82-89.

Iova, O. M., Marin, G. E., Lazar, I., Stanescu, I., Dogaru, G., Nicula, C. A., & Bulboaca, A. E. (2023). Nitric Oxide/Nitric Oxide Synthase System in the Pathogenesis of Neurodegenerative *Disorders—An Overview. Antioxidants, 12*(753), 15-25.

Janaszak-Jasiecka, A., Ploska, A., Wieronska, J. M., Dobrucki, L. W., & Kalinowski, L. (2023). Endothelial dysfunction due to eNOS uncoupling: Molecular mechanisms as potential therapeutic targets. *Cellular and Molecular Biology Letters, 28,* 21-26.

Jang, D. I., Lee, A. H., Shin, H. Y., Song, H. R., Park, J. H., Kang, T. B., Lee, S. R., & Yang, S. H. (2021). The Role of Tumor Necrosis Factor Alpha (TNF-alpha) in Autoimmune Disease and Current TNF-alpha Inhibitors in Therapeutics. *International Journal of Molecular Sciences, 22,* 19-27.

Jayaraj, R. L., Azimullah, S., Beiram, R., Jalal, F. Y., & Rosenberg, G. A. (2019). Neuroinflammation: Friend and foe for ischemic stroke. *Journal of Neuroinflammation, 16*, 142-144.

Kavanaugh, A., & Gottlieb, A. (2017). Rheumatoid arthritis and cardiovascular risk. *The Lancet, 389*(10065), 1552-1564.

Kim, M. E., & Lee, J. S.(2025). Advances in the Regulation of Inflammatory Mediators in Nitric Oxide Synthase: Implications for Disease

Modulation and Therapeutic Approaches. *International Journal of Molecular Sciences, 26*(3), 1204.
Kitasato, H., & Furuya, T. (2021). Endothelial dysfunction and thrombosis in rheumatoid arthritis. *Journal of Rheumatology, 48*(7), 1012-1020.
Krol, M., & Kepinska, M. (2020). Human Nitric Oxide Synthase-Its Functions, Polymorphisms, and Inhibitors in the Context of Inflammation, Diabetes and Cardiovascular Diseases. *International Journal of Molecular Sciences*, *22*, 10-56.
Lavy, M., Gauttier, V., Poirier, N., Barille-Nion, S., & Blanquart, C. (2021). Specialized Pro-Resolving Mediators Mitigate Cancer-Related Inflammation: Role of Tumor- Associated Macrophages and Therapeutic Opportunities. *Frontier Immunology, 12,* 702785.
Liao, Z., Zheng, R., & Shao, G. (2023). Mechanisms and application strategies of miRNA-146a regulating inflammation and fibrosis at molecular and cellular levels (Review). *International Journal of Molecular Medicine, 51*, 1-16.
Luo, M. He, N., Xu, Q., Wen, Z., Wang, Z., Zhao, J., & Liu, Y. (2024). Roles of prostaglandins in immunosuppression. *Clinical Immunology, 265*, 110298.
Maghsoudi, H., Sheikhnia, F., Sitarek, P., Hajmalek, N., Hassani, S., Rashidi, V., Khodagholi, S., Mir, S. M., Malekinejad, F., & Kheradmand, F. (2023). The Potential Preventive and Therapeutic Roles of NSAIDs in Prostate Cancer. *Cancers, 15,* 54-67.
Malavolta, M., & Santoro, A. (2018). Biomarkers in the treatment of rheumatoid arthritis. *Autoimmunity Reviews*, *17*(3), 231-239.
Mintz, J., Vedenko, A., Rosete, O., Shah, K., Goldstein, G., Hare, J. M., Ramasamy, R., & Arora, H. (2021). Current Advances of Nitric Oxide in Cancer and Anticancer Therapeutics. *Vaccines*, *9*, 94-96.
Pashangzadeh, S., Motallebnezhad, M., Vafashoar, F., Khalvandi, A. & Mojtabavi, N. (2021). Implications the Role of miR-155 in the Pathogenesis of Autoimmune Diseases. *Frontier Immunology, 12*, 669382.
Perez-Torres, I., Manzano-Pech, L., Rubio-Ruiz, M. E., Soto, M. E., & Guarner-Lans, V. (2020). Nitrosative Stress and Its Association with Cardiometabolic Disorders. *Molecules, 25,* 25-55.
Ren, H., Han, R., Chen, X., Liu, X., Wan, J., Wang, L., Yang, X., & Wang, J. (2020). Potential therapeutic targets for intracerebral hemorrhageassociated inflammation: An update. *Journal of Cerebral Blood Flow & Metabolism, 40*, 68-75.
Roy, R., Wilcox, J., Webb, A. J., & O'Gallagher, K. (2023). Dysfunctional and Dysregulated Nitric Oxide Synthases in Cardiovascular Disease: Mechanisms and Therapeutic Potential. *International Journal of Molecular Sciences, 24*, 15-25.
Salar, M.Z., Bibi, Z., Hassan, T., Hussain A. & Ijaz, M.U. (2024). Cellular crossroads: Oxidative stress, inflammation and apoptosis in molecular biology. In: Zoology: Advancements and Research Trends (Ijaz M.U., Ehsan, N., Imran, M. & Yousaf, S. eds): FahumSci, Lahore, Pakistan, pp: 37-43.
Salvagno, M., Sterchele, E. D., Zaccarelli, M., Mrakic-Sposta, S., Welsby, I. J., Balestra, C., & Taccone, F. S. (2024). Oxidative Stress and Cerebral Vascular Tone: The Role of Reactive Oxygen and Nitrogen Species. *International Journal of Molecular Sciences, 25*, 3007.
Scioli, M. G., Storti, G., D'Amico, F., Rodriguez Guzman, R., Centofanti, F., Doldo, E., Cespedes Miranda, E. M., & Orlandi, A. (2020). Oxidative Stress and New Pathogenetic Mechanisms in Endothelial Dysfunction: Potential Diagnostic Biomarkers and Therapeutic *Targets. Journal of Clinical Medicine, 8*, 10-20.
Silman, A. J., & Pearson, J. E. (2018). Epidemiology and genetics of rheumatoid arthritis. *Arthritis Research & Therapy*, *4*(3), S265-S272.
Smith, J., & Garcia, L. (2020). Mechanisms of inflammation in rheumatoid arthritis: Implications for therapy. *Clinical Immunology, 212*, 108-115.
Smolen, J. S., Aletaha, D., & McInnes, I. B. (2016). Rheumatoid arthritis. *The Lancet, 388*(10055), 2023-2038.
Somasundaram, V., Basudhar, D., Bharadwaj, G., No, J. H., Ridnour, L. A., Cheng, R. Y. S., Fujita, M., Thomas, D. D., Anderson, S. K., McVicar, D. W., et al. (2019). Molecular Mechanisms of Nitric Oxide in Cancer Progression, Signal Transduction, and Metabolism. *Antioxidant & Redox Signaling, 30*, 24-43.
Stykel, M. G., & Ryan, S. D. (2022). Nitrosative stress in Parkinson's disease. *NPJ Parkinson's Disease*, *8*, 104-110.
Sundararajan, V. (2025). Gene expression analysis reveals mir-29 as a linker regulatory molecule among rheumatoid arthritis, inflammatory bowel disease, and dementia: Insights from systems biology approach. *PloS One*, *20*(1), 65-84.
Tabish, T. A., Crabtree, M. J., Townley, H. E., Winyard, P. G., & Lygate, C. A. (2024). Nitric Oxide Releasing Nanomaterials for Cardiovascular Applications. *JACC: Basic Translational Science, 9*, 69-70.
Tian, M., Yuan, Y. C., Li, J. Y., Gionfriddo, M. R., & Huang, R. C. (2015). Tumor necrosis factor-alpha and its role as a mediator in myocardial infarction: A brief review. *Chronic Diseases and Translational Medicine, 1*, 18-26.
Tiosano, S., Watad, A., & Bragazzi, N. L. (2021). The role of oxidative stress in the pathogenesis of rheumatoid arthritis. *Journal of Clinical Medicine*, *10*(11), 2431.
Xue, J., Nian, M., Liang, Y., Zhu, Z., Hu, Z., Jia, Y., Chi, S., & Chen, J. (2025). Neutrophil extracellular traps (NETs) are increased in rheumatoid arthritis-associated interstitial lung disease. *Respiratory Research, 26*(1), 1-19.
Yoon, S., Eom, G. H., & Kang, G. (2021). Nitrosative Stress and Human Disease: Therapeutic Potential of Denitrosylation. *International Journal of Molecular Sciences, 22*, 94-97.
Yoshida, T., Okumura, T., Matsuo, Y., Okuyama, T., Michiura, T., Kaibori, M., Umezaki, N., Bono, H., Hirota, K., & Sekimoto, M. (2022). Activation of transcription factor HIF inhibits IL-1beta-induced NO production in primary cultured rat hepatocytes. *Nitric Oxide, 124*, 1-14.
Yu, X., & Zhao, M. (2022). Advanced therapeutic approaches in the management of rheumatoid arthritis: From DMARDs to biologics. *Current Opinion in Rheumatology*, *34*(4), 404-41.
Zeng, Y., Buonfiglio, F., Li, J., Pfeiffer, N., & Gericke, A. (2025). Mechanisms Underlying Vascular Inflammaging: Current Insights and Potential Treatment Approaches. *Aging and Disease, 16*(5), 2-5.
Zhu, L. J., Li, F., & Zhu, D. Y. (2023). nNOS and Neurological, Neuropsychiatric Disorders: A 20-Year Story. *Neuroscience Bulletin, 39*, 1439-1453.
Ziegler, K., Kunert, A. T., Reinmuth-Selzle, K., Leifke, A. L., Widera, D., Weller, M. G., Schuppan, D., Frohlich-Nowoisky, J., Lucas, K., & Poschl, U. (2020). Chemical modification of pro-inflammatory proteins by peroxynitrite increases activation of TLR4 and NF-kappaB: Implications for the health effects of air pollution and oxidative stress. *Redox Biology, 37,* 101581.